EMERYVILLE, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time
| Toll Free: | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 7186111 |
| Webcast: | http://public.viavid.com/index.php?id=129538 |
| Replays, available through May 23rd | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 7186111 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
Andrew@LifeSciAdvisors.com